Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Ipca Laboratories
Large Cap•17,335 Employees•IPO 1994
Current Price
₹1561.30
0.5 (0.03%)Updated
Today's Range
1537.4
₹1561.30
1576.7
52 Week Range
52W Low₹1168.20
52W High₹1595.00
₹1561.30
Downside33.65%
Upside2.16%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹37,863.71 Cr
Market Cap
Total market value of companyP/E Ratio
45.75
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
4.57
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹32.78
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
4.87%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
14.70%
ROCE
Return on Capital Employed. >15% is goodNet Margin
8.89%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
3.94%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
13.97%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
10.30%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
21.30%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.20
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹273.88
Book Value
Net asset value per shareDividend Yield
0.27%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
44.70%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
4 points- •Ipca Laboratories boasts a healthy Return on Equity (ROE) of 12.8% and Return on Capital Employed (ROCE) of 14.7%, indicating efficient use of shareholder investments and strong operational profitability.
- •The company demonstrates robust quarterly performance with sales growth of 10.3% and a significant 21.3% increase in quarterly profit, showcasing consistent market demand and effective management.
Weaknesses
5 points- •The company's Price-to-Earnings (P/E) ratio of 36.50 is relatively high compared to peers like Cipla (23.65) and Dr Reddy's (18.09), potentially indicating the stock might be overvalued.
- •Recent stock price movements show some volatility and declines, with a wide 52-week range from ₹1168 to ₹1758, indicating potential market uncertainty and significant price fluctuations.
Opportunities
4 points- •The growing global demand for pharmaceutical products, driven by an aging population and increasing healthcare awareness, presents a significant market expansion opportunity for Ipca Laboratories.
- •Expansion into new therapeutic areas or emerging markets could unlock substantial revenue growth. Diversifying product offerings can also reduce dependency on existing portfolios.
Threats
5 points- •Intense competition from larger, well-established pharmaceutical players, as seen in the peer data, could exert pressure on pricing and market share, impacting Ipca's profitability.
- •Stringent and evolving regulatory policies in the pharmaceutical sector, including drug pricing controls and approval processes, pose a continuous risk to operational flexibility and revenue.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
Recent Insider Transactions
| Insider Name | Transaction Date | Filing Date | Total Shares | Change | Price | Action |
|---|---|---|---|---|---|---|
Mrs. Usha M. Chandurkar | 18 Dec 2024 | 19 Dec 2024 | 43.02 L | 40.00 L | ₹1,499.25 | SELL |
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹1658.13 | +₹96.83 | +6.20% |
| R3 | ₹1618.83 | +₹57.53 | +3.68% |
| R2 | ₹1597.77 | +₹36.47 | +2.34% |
| R1 | ₹1579.53 | +₹18.23 | +1.17% |
| PIVOT | ₹1558.47 | -2.83 | -0.18% |
| CURRENT | ₹1561.30 | - | - |
| S1 | ₹1461.63 | -₹99.67 | -6.38% |
| S2 | ₹1500.93 | -₹60.37 | -3.87% |
| S3 | ₹1519.17 | -₹42.13 | -2.70% |
| S4 | ₹1540.23 | -₹21.07 | -1.35% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume+190.8% vs avg
5.91L
(13 Mar 2026)Delivery %+24.6% vs avg
76.2%
(13 Mar 2026)Avg Volume (20D)20-day average
2.03L
(13 Feb - 13 Mar)Avg Delivery %Trend ↑
51.6%
(13 Feb - 13 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Laurus Labs Ltd
883.00 %
Highest Dividend Yield
Glaxosmithkline Pharmaceuticals Ltd
3.32 %
Peer Comparison
| Company Name |
|---|
 Abbott India Ltd |
 Ajanta Pharma Ltd |
 Alkem Laboratories Ltd |
 Astrazeneca Pharma India Ltd |
 Aurobindo Pharma Ltd |
 Cohance Lifesciences Ltd |
 Emcure Pharmaceuticals Ltd |
 Gland Pharma Ltd |
 Glaxosmithkline Pharmaceuticals Ltd |
 Glenmark Pharmaceuticals Ltd |
 J B Chemicals & Pharmaceuticals Ltd |
 Laurus Labs Ltd |
 Pfizer Ltd |
 Piramal Pharma Ltd |
 Sun Pharmaceutical Industries Ltd |
 Wockhardt Ltd |
About
Ipca Laboratories Ltd
Ipca Laboratories Limited is a multinational pharmaceutical company with a long history, established in 1949 and headquartered in Mumbai, India. The company operates across a broad global footprint, distributing its products to India, Europe, Africa, the Americas, Asia, the CIS region, and Australasia. Their business model is vertically integrated, encompassing both the manufacture and marketing of their products.
A significant portion of Ipca's business involves the production and sale of Active Pharmaceutical Ingredients (APIs). These APIs are key components in the creation of various medications and are provided for a wide range of therapeutic applications. Specifically, Ipca focuses on APIs for anti-hypertensive, anti-malarial, diuretic, DMARD (disease-modifying antirheumatic drug), and anthelmintic treatments. This focus on APIs demonstrates Ipca's commitment to supplying crucial components to the broader pharmaceutical industry.
In addition to APIs, Ipca manufactures and markets a diverse portfolio of both generic and branded pharmaceutical formulations. These formulations cover an extensive range of therapeutic areas, indicating a wide-ranging approach to healthcare needs. These areas include allergy, oncology (anti-neoplastic/cancer drugs), arthritis, epilepsy, cardiology, diabetes, dermatology, gastroenterology, hematology, infectious diseases, neurology, pain management (neuropathic pain and NSAIDs), ophthalmology, orthopedics, psychiatry, respiratory ailments, rheumatology, and urology. Furthermore, they also offer nutraceuticals and probiotics, expanding their reach into complementary health products.
Ipca's global reach is a key component of its business strategy. The company actively exports its products worldwide, showcasing its ability to compete and succeed in international markets. This international focus suggests a commitment to serving global healthcare needs and a capacity to adapt to diverse regulatory and market landscapes. The breadth of its product offerings, from APIs to a wide variety of formulations, positions Ipca to participate in numerous segments of the pharmaceutical market.
COMPANY FACTS - IPCALAB
Registered Address
125, Kandivli Industrial Estate, Kandivli (West),
Mumbai
MAHARASHTRA
IN
Tel: 912262105000
Website:https://www.ipca.com/
Investor Relations:http://www.ipca.com/investors-annual-reports/
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 17,335
IPO Date: 23/02/1994
MANAGEMENT - IPCALAB
Shri. Premchand Godha
Executive Chairman of the Board
Mr. Pranay Godha
Chief Executive Officer, Managing Director, Executive Director
Mr. Ajit Jain
Chief Financial Officer, Managing Director, Executive Director
Mr. Pabitra Bhattacharya
President - Operations (API)
Mr. Sunil Ghai
President - Marketing
Dr. Sanjay Kapadia
President - Corporate Quality Assurance
Dr. Ashok Kumar
President - Research and Development (Chemicals)
Mr. Shailesh Laul
President - Operations (Formulations)
Mr. Hitesh Maheshwari
President - Research and Development (Formulations)
Mr. Shashil Mendonsa
President - International Marketing
Mr. Saidutta Nanda
President Human Resources
Dr. Anil Pareek
President - Medical Affairs and Clinical Research
Investor Questions Answered
Ipca Laboratories Ltd (IPCALAB) Stock FAQs
Get answers to the most common questions about Ipca Laboratories Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Ipca Laboratories Ltd (IPCALAB) is ₹1,561.3. Today, the stock has gained by ₹0.50 (0.03%), trading in a range of ₹1,537.4 to ₹1,576.7. The stock opened at ₹1,567 with a trading volume of 5,90,960 shares.
Ipca Laboratories Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹37,863.71 crores, P/E ratio of 45.75, ROE of 4.87%, and ROCE of 14.70%. The dividend yield stands at 0.27%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Ipca Laboratories Ltd (IPCALAB) is ₹1,595, while the 52-week low is ₹1,168.2. Currently trading at ₹1,561.3, the stock is 92.1% away from its 52-week low and 2.1% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Ipca Laboratories Ltd stock at ₹1,561.3 depends on multiple factors. The stock is currently trading with a P/E ratio of 45.75 and P/B ratio of N/A. Today's performance shows a gain of 0.03%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Ipca Laboratories Ltd offers a dividend yield of 0.27%, which means for every ₹100 invested at the current price of ₹1,561.3, you can expect to receive approximately ₹0.27 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Ipca Laboratories Ltd's key financial metrics include: P/E Ratio: 45.75, P/B Ratio: N/A, ROE: 4.87%, ROCE: 14.70%, Dividend Yield: 0.27%, EPS: ₹32.78, Book Value: ₹273.88, Debt-to-Equity: 0.20, and Current Ratio: N/A. The company's market cap stands at ₹37,863.71 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Ipca Laboratories Ltd stock opened at ₹1,567 and is currently trading at ₹1,561.3, showing a gain of ₹0.50 (0.03%). The intraday high is ₹1,576.7 and low is ₹1,537.4. The trading volume stands at 5,90,960 shares, indicating moderate market participation today.
Ipca Laboratories Ltd has a Price-to-Earnings (P/E) ratio of 45.75, which means investors are willing to pay ₹45.75 for every ₹1 of earnings. With an EPS of ₹32.78, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Ipca Laboratories Ltd has a market capitalization of ₹37,863.71 crores, making it a mid-cap company. Market cap is calculated by multiplying the current stock price (₹1,561.3) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Ipca Laboratories Ltd has a book value of ₹273.88 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹1,561.3, which is 470.1% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Ipca Laboratories Ltd has a Return on Equity (ROE) of 4.87% and Return on Capital Employed (ROCE) of 14.70%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Ipca Laboratories Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Ipca Laboratories Ltd has a debt-to-equity ratio of 0.20, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Ipca Laboratories Ltd has an Earnings Per Share (EPS) of ₹32.78, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹1,561.3 and P/E ratio of 45.75, investors are paying 45.75 times the annual earnings per share. This moderate EPS suggests decent earnings generation. Track EPS growth over quarters to assess earnings momentum.
Ipca Laboratories Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Ipca Laboratories Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Ipca Laboratories Ltd stock, consider: 1) Fundamental Analysis - Review P/E (45.75), ROE (4.87%), debt-to-equity (0.20), and growth rates. 2) Technical Analysis - Check 52-week range (₹1168.20 - ₹1595.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹1561.30) with book value (₹273.88) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Ipca Laboratories Ltd share is ₹1.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹1,561.3 is 156030x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Ipca Laboratories Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹1168.20 - ₹1595.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.20 indicates leverage. 4) Liquidity Risk - Based on trading volume of 5,90,960 shares. 5) Valuation Risk - P/E of 45.75 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Ipca Laboratories Ltd operates in the industry with key metrics: P/E ratio of 45.75, ROE of 4.87%, market cap of ₹37,863.71 crores, and dividend yield of 0.27%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.20), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Ipca Laboratories Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹1,561.3, with a 52-week range of ₹1168.20 to ₹1595.00. Based on fundamentals like P/E (45.75), ROE (4.87%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Ipca Laboratories Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹1561.30. 2) Fundamental Deterioration - Declining ROE (currently 4.87%), increasing debt (D/E: 0.20), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Ipca Laboratories Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.27%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu